{"id":"placebo-of-kw21052","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo formulation for KW21052, this product is inert and serves as a control comparator in clinical trials. It is designed to match the appearance and administration route of the active drug to maintain blinding in phase 3 studies.","oneSentence":"This is a placebo control and contains no active pharmaceutical ingredient.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:51:37.033Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01863810","phase":"PHASE3","title":"Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain","status":"UNKNOWN","sponsor":"KunWha Pharmaceutical Co., Ltd.","startDate":"2013-08","conditions":"Diabetic Neuropathy","enrollment":394}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of KW21052","genericName":"Placebo of KW21052","companyName":"KunWha Pharmaceutical Co., Ltd.","companyId":"kunwha-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}